Connect your AI

PTC Therapeutics PTCT Non-Cash Lease Expense

Non-Cash Lease Expense at other companies

BridgeBio PharmaBBIO

$1.47M+47.5%

Other financials

Income statement

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Profitability

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

Return on equity-216.7%—

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.

The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's non-cash lease expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is PTC Therapeutics's non-cash lease expense?: PTC Therapeutics (PTCT) reported non-cash lease expense of $1.76M in Q1 2026.
How has PTC Therapeutics's non-cash lease expense changed year-over-year?: PTC Therapeutics's non-cash lease expense decreased by 1.6% year-over-year, from $1.79M to $1.76M.
What is the long-term trend for PTC Therapeutics's non-cash lease expense?: Over 4 years (2021 to 2025), PTC Therapeutics's non-cash lease expense has grown at a 0.3% compound annual growth rate (CAGR), from $7.39M to $7.47M.
What does non-cash lease expense mean?: Non-cash portion of operating lease cost — the difference between straight-line lease expense and actual cash rent payments.